The new Express License service removes barriers to accessing this transformative gene editing technology for startups.  An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license.  DUBLIN, IRELAND and CHESHIRE, UK – 13th January 2025: ERS Genomics (‘ERS’), the CRISPR licensing company, today announces the launch of its Express License platform to provide small research enterprises and startups with affordable and rapid access to the world’s largest foundational and essential CRISPR/Cas9 patent portfolio.   Trusted by leading innovators worldwide, ERS Genomics is committed to providing responsible and effective access to